Moderna vs. Pfizer: Is There a “Best” mRNA Vaccine?

Both of the mRNA vaccines available in the US are highly effective against severe COVID-19, but recent studies suggest that Moderna’s elicits a stronger immune response and might be better at preventing breakthrough infections.

alejandra manjarrez
| 10 min read
moderna and pfizer vaccine vials with syringes and a mask

Register for free to listen to this article
Listen with Speechify
0:00
10:00
Share

ABOVE: © ISTOCK.COM, CARMENGABRIELA

#TeamPfizer and #TeamModerna are two of the captions often found next to selfies of proud newly vaccinated people on social media. And both groups do have a reason to celebrate as the two mRNA vaccines available in the US have proved to be highly effective against severe COVID-19.

#TeamModerna when #TeamPfizer walks in. pic.twitter.com/5UimFI4rBf

Research published in recent weeks, however, suggests the Moderna vaccine’s advantage in terms of long-term protection. In multiple independent studies, significantly lower antibody levels and more vaccine breakthrough infections have been detected in the Pfizer/BioNTech-vaccinated population. These could be explained by a myriad of slight differences between the vaccines themselves: their distinct dosages, the intervals between the two doses, or the composition of the lipid nanoparticles used in each one. For now, all possibilities remain open.

By comparing vaccines and exploring the basis of their differences, “we are going to learn a ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Keywords

Meet the Author

  • alejandra manjarrez

    Alejandra Manjarrez, PhD

    Alejandra Manjarrez is a freelance science journalist who contributes to The Scientist. She has a PhD in systems biology from ETH Zurich and a master’s in molecular biology from Utrecht University.
Share
May digest 2025 cover
May 2025, Issue 1

Study Confirms Safety of Genetically Modified T Cells

A long-term study of nearly 800 patients demonstrated a strong safety profile for T cells engineered with viral vectors.

View this Issue
iStock

TaqMan Probe & Assays: Unveil What's Possible Together

Thermo Fisher Logo
Meet Aunty and Tackle Protein Stability Questions in Research and Development

Meet Aunty and Tackle Protein Stability Questions in Research and Development

Unchained Labs
Detecting Residual Cell Line-Derived DNA with Droplet Digital PCR

Detecting Residual Cell Line-Derived DNA with Droplet Digital PCR

Bio-Rad
How technology makes PCR instruments easier to use.

Making Real-Time PCR More Straightforward

Thermo Fisher Logo

Products

The Scientist Placeholder Image

Biotium Launches New Phalloidin Conjugates with Extended F-actin Staining Stability for Greater Imaging Flexibility

Leica Microsystems Logo

Latest AI software simplifies image analysis and speeds up insights for scientists

BioSkryb Genomics Logo

BioSkryb Genomics and Tecan introduce a single-cell multiomics workflow for sequencing-ready libraries in under ten hours

iStock

Agilent BioTek Cytation C10 Confocal Imaging Reader

agilent technologies logo